Glycomine has announced that it has completed enrollment in its Phase 2b POLAR study for a rare genetic disorder.

 

The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). Currently, no approved treatments exist.

 

“The Phase 2b POLAR study will build on the encouraging results observed in our open-label Phase 2a study of GLM101, which demonstrated meaningful improvements in ataxia and other clinical endpoints with a favorable safety profile,” said Rose Marino, Chief Medical Officer of Glycomine. 

 

“We are grateful to the patients, families, caregivers and investigators who have made these trials possible.”

 

The trial has treated 43 pediatric and adult patients, ages 4 to 47, across 15 sites in the US, UK, and Europe. 

 

The study’s primary goal is to measure improvement in ataxia after 24 weeks using the International Cooperative Ataxia Rating Scale (ICARS).